Teladoc Health (TDOC) Scheduled to Post Earnings on Thursday

Teladoc Health (NYSE:TDOC) is set to announce its earnings results after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. Teladoc Health had a negative net margin of 8.47% and a negative return on equity of 9.22%. The company had revenue of $660.50 million during the quarter, compared to analysts’ expectations of $670.79 million. During the same quarter in the previous year, the company earned ($0.23) earnings per share. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Price Performance

TDOC opened at $13.14 on Thursday. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of -9.80 and a beta of 0.94. The company has a fifty day moving average of $15.89 and a two-hundred day moving average of $17.98. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. Teladoc Health has a fifty-two week low of $13.03 and a fifty-two week high of $30.41.

Insider Activity

In other news, CEO Jason N. Gorevic sold 53,755 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $780,522.60. Following the sale, the chief executive officer now directly owns 653,073 shares in the company, valued at $9,482,619.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Jason N. Gorevic sold 53,755 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $780,522.60. Following the sale, the chief executive officer now owns 653,073 shares of the company’s stock, valued at approximately $9,482,619.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CTO Nikolaos P. Nanis sold 2,866 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $41,614.32. Following the sale, the chief technology officer now directly owns 69,850 shares in the company, valued at approximately $1,014,222. The disclosure for this sale can be found here. Over the last three months, insiders sold 135,441 shares of company stock valued at $2,038,251. 1.63% of the stock is owned by company insiders.

Institutional Trading of Teladoc Health

A number of hedge funds have recently modified their holdings of TDOC. Price T Rowe Associates Inc. MD grew its stake in shares of Teladoc Health by 12.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 81,189 shares of the health services provider’s stock valued at $1,750,000 after buying an additional 9,039 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in Teladoc Health by 4.3% in the fourth quarter. Public Employees Retirement System of Ohio now owns 70,120 shares of the health services provider’s stock valued at $1,511,000 after purchasing an additional 2,912 shares in the last quarter. Vanguard Group Inc. raised its stake in Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock valued at $377,451,000 after purchasing an additional 1,855,480 shares in the last quarter. Oracle Alpha Inc. acquired a new position in Teladoc Health in the fourth quarter valued at about $250,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Teladoc Health in the 4th quarter valued at approximately $550,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on TDOC shares. Leerink Partnrs reiterated a “market perform” rating on shares of Teladoc Health in a report on Monday, February 26th. Barclays dropped their target price on shares of Teladoc Health from $26.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 21st. Citigroup decreased their price target on shares of Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, February 21st. Piper Sandler lowered their price objective on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, February 21st. Finally, Canaccord Genuity Group reduced their price target on shares of Teladoc Health from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, February 21st. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $22.23.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.